CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
CPXX was delisted on the 11th of July, 2016.
6 hedge funds and large institutions have $10.4M invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$7.7M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.33M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.85K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.6K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$548 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
1
Caxton Corporation
Princeton,
New Jersey
| $7.3M | +$7.7M | +2,246,469 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.18M | +$2.33M | +679,592 | New |
|
|
OM
3
Opaleye Management
Boston,
Massachusetts
| $961K | +$1.06M | +310,000 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $2K | +$1.6K | +467 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2K | +$1.85K | +540 | New |
|
|
U
6
UBS
Zurich,
Switzerland
| $1K | +$548 | +160 | New |
|
CPXX Hedge Fund Activity: Q4 2013 in Review
6 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q4 2013, worth a combined $10.4M.
Buyers outnumbered sellers: 6 funds opened new CPXX positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Caxton Corporation, opening a new position worth an estimated $7.7M.
- 6 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $10.4M of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q4 2013.
- 6 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q4 2013 and 0 closed out, a net change of +6 holders.
- The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK buyer in Q4 2013 was Caxton Corporation, an estimated $7.7M added.
Based on aggregated 13F filings for Q4 2013.